Physician profile
Brooke E Hotop
NPI 1124642764
$4,017.71
in general payments reported to CMS, 2019-2025
28 companies · $946 in 2025
The $946 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $1,123 · 2023: $641 · 2024: $1,114 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.07 | 2021-2025 | |
| Lilly USA, LLC | $353.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $343.39 | 2021-2025 | |
| Novo Nordisk INC | $239.28 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.57 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $116.04 | 2022-2024 | Farxiga, Breztri |
| Amgen INC. | $105.40 | 2022-2024 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $100.12 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $99.15 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.62 | 2022 | |
| Glaxosmithkline, LLC. | $83.61 | 2022-2024 | Shingrix, Arexvy |
| Medtronic, INC. | $57.88 | 2025 | Inceptiv |
| Exact Sciences Corporation | $56.23 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.57 | 2025 | Caplyta |
| Amarin Pharma, INC. | $36.24 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.87 | 2024-2025 | Voquezna |
| Dexcom, INC. | $32.88 | 2022-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $32.36 | 2021 | |
| Merck Sharp & Dohme LLC | $32.27 | 2023-2024 | Verquvo, Capvaxive, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $29.34 | 2021 | |
| Pfizer INC. | $21.06 | 2025 | |
| Sumitomo Pharma America, INC. | $17.19 | 2025 | Gemtesa |
| Astellas Pharma US INC | $17.02 | 2024 | Veozah |
| Lundbeck LLC | $16.28 | 2025 | Rexulti |
| Viatris Specialty LLC | $14.38 | 2025 | Yupelri |
| Supernus Pharmaceuticals, INC. | $14.29 | 2022 | |
| Sanofi Pasteur INC. | $14.16 | 2022 | |
| Organon LLC | $4.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Hotop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.